In a preclinical study the therapeutic efficacy of an anti-CAIX mAb conjugated drug with an average drug-to-antibody ratio of n=∼4 showed a positive correlation with tumor CAIX expression level determined by immunohistochemistry and ELISA in tumor models [24]. Here, CA9 is linked to neoplasm.